What does Therini Bio, Inc. do?
Therini Bio is a clinical-stage biotechnology company focused on developing fibrin-targeting immunotherapies to treat neurodegenerative diseases driven by vascular dysfunction.
How much did they raise?
The company raised $39M in a Series A extension round led by Angelini Ventures and Apollo Health Ventures, adding to a total Series A financing of $75M with participation from SV Health Investors’ Biotech Fund, Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures, and the Foundation for a Better World.
What are their plans for the money?
The funds will be used to fund Phase 1b trials of its lead candidate, THN391, for the treatment of Alzheimer’s Disease and Diabetic Macular Edema, as well as to support the development of a fibrin/VEGF bispecific, potentially setting the stage for groundbreaking advances in neurodegenerative disease therapies.
What have they achieved so far?
Preclinical studies demonstrated that THN391 effectively prevents vascular and neuronal degeneration, and a recent Phase 1a trial confirmed that the drug is well-tolerated with a favorable pharmacokinetic profile, marking significant progress toward its clinical development.
